Malaria Studies in Cambodia

This study has been completed.
Sponsor:
Information provided by:
National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:
NCT00663546
First received: April 19, 2008
Last updated: January 14, 2014
Last verified: December 2013
  Purpose

This study, conducted by the National Center for Parasitology, Entomology and Malaria Control of Cambodia s Ministry of Health and the National Institute of Allergy and Infectious Diseases, will explore whether the following factors confer protection against malaria and associated anemia: certain blood groups, the hemoglobin E variant, G6PD-deficiency and alpha-thalassemia. Malaria is caused by parasites (P. falciparum and P. vivax) that are transmitted to humans through mosquito bites. This protocol includes two studies, a cohort study and a P. vivax collection study.

Individuals are eligible for enrollment in the studies as follows:

Cohort study:

Residents of all ages of Kandal, Ekapheap and Sangkumthmey villages (Thmar Da commune) who plan to remain in Thmar Da commune for the next 5 years.

P. vivax collection study:

2 years of age and older

Participating in NIAID protocol 05-I- N210 ( Severe Malaria and Anti-malarial Drug Resistance in Cambodia ) and diagnosed with P. vivax malaria

Participants undergo the following procedures:

Cohort study:

Baseline evaluation, including the following:

  • Collection of demographic information
  • Malaria history, temperature measurement and review of current symptoms, if any
  • Blood draw of 300 microliters
  • Additional blood draw of 10 milliliters in selected adults 18 years of age and older

Treatment with artesunate-piperaquine at a commune health post for subjects who develop malaria

Contact once a year for 5 years to determine continued residency in Thmar Da commune

P. vivax collection study:

  • Medical history and physical examination
  • Hemoglobin level measurement
  • Blood draw
  • Treatment with chloroquine
  • Blood draw 3 to 5 weeks after treatment in some patients 18 years of age or older

Condition
Malaria

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Studies of P. Vivax and P. Falciparum Malaria in Cambodia

Resource links provided by NLM:


Further study details as provided by National Institutes of Health Clinical Center (CC):

Estimated Enrollment: 2765
Study Start Date: March 2008
Estimated Study Completion Date: December 2013
Detailed Description:

Cohort study. Hemoglobin (Hb) and red blood cell (RBC) polymorphisms that give rise to HbE, alpha-thalassemia, G6PD-deficiency, and ABO blood groups occur at high frequency along the Thailand-Cambodia border, where Plasmodium vivax and P. falciparum have been and continue to be transmitted. To determine whether these Hb/RBC polymorphisms have been naturally selected because they confer protection against malaria and malaria-associated anemia, we will conduct a cohort study of ethnic Khmer in Cambodia. Approximately 1000 individuals of all ages will be genotyped for the four polymorphisms listed above and then followed for 5 years to determine the mean incidence rates for both P. vivax and P. falciparum malaria, stratified by genotype. Incidence rate ratios (IRRs) will be calculated for each polymorphism relative to the wildtype genotype. Differences between Hb levels during acute episodes of malaria and Hb levels at baseline will also be calculated to determine if Hb/RBC polymorphisms influence the degree of malaria-associated anemia.

P. vivax collection study. Unlike P. falciparum, P. vivax cannot be efficiently cultivated in vitro. Improved cultivation methods are needed to make progress on nearly all aspects of P. vivax malariology, including pathogenesis, naturally-acquired immunity, vaccination, and antimalarial drug resistance. We plan to improve both short- and long-term cultivation methods in order to test various hypotheses of P. vivax pathogenesis and protection. Using freshly obtained parasite isolates from individuals with P. vivax malaria, we will test whether Hb/RBC polymorphisms influence potentially pathogenic properties of P. vivax parasites, such as their ability to bind non-infected RBCs and other host cells. It is believed that P. vivax selectively invades reticutocytes. This tropism has frustrated attempts at long-term cultivation of this parasite, which requires a constant source of reticulocyte-rich blood not easily obtained even in developed countries. The host reticulocyte receptor that mediates the highly selective tropism of P. vivax has not been identified. Fresh P. vivax parasites will also be used in in vitro experiments to identify the putative receptor that defines reticulocyte tropism. Any P. vivax ligand that bound selectively to a reticulocyte receptor will then be discovered and worked up as a promising vaccine candidate.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria
  • INCLUSION CRITERIA: (Cohort Study)

Resident of Kandal, Ekapheap, and Sangkumthmey villages (Thmar Da commune), and no plans to leave the Thmar Da commune for the next 5 years.

Willingness to participate in the study as evidenced by informed consent of subjects or his/her parent or guardian, and willingness to come to commune health posts if he/she develops fever or other symptoms of malaria.

Individuals of all ages will be enrolled.

EXCLUSION CRITERIA: (Cohort Study)

Any condition that in the opinion of the investigator would render the subject unable to comply with the protocol (e.g., psychiatric disease).

Any health condition that in the opinion of the investigator would confound data analysis or pose unnecessary exposure risks to study personnel (e.g., individuals who are known to be HIV-infected or to have AIDS).

INCLUSION CRITERIA: (P. vivax Collection Study)

P. vivax malaria (mono-infection).

Willingness to participate in the study as evidenced by informed consent of subjects or his/her parent or guardian.

Age greater than or equal to 2.

Hematocrit greater than or equal to 25%.

EXCLUSION CRITERIA: (P. vivax Collection Study)

Any condition that in the opinion of the investigator would render the subject unable to comply with the protocol (e.g., psychiatric disease).

Any health condition that in the opinion of the investigator would confound data analysis or pose unnecessary exposure risks to study personnel (e.g., individuals who are known to be HIV-infected or to have AIDS).

Pregnancy.

Prior use of antimalarials during the past 2 months.

INCLUSION CRITERIA: (Cord and Peripheral Blood Collection Study)

Healthy male or female adults greater than or equal to 18 years old or healthy pregnant female adults greater than or equal to 18 years old.

Willingness to participate in the study as evidenced by informed consent.

EXCLUSION CRITERIA: (Cord and Peripheral Blood Collection Study)

Any condition that in the opinion of the investigator would render the subject unable to comply with the protocol (e.g., psychiatric disease).

Any health condition that in the opinion of the investigator would confound data analysis or pose unnecessary exposure risks to study personnel (e.g., individuals who are known to be HIV-infected or to have AIDS).

INCLUSION CRITERIA: (Collection of peripheral blood for identifying and isolating memory B cells)

Healthy male or non- pregnant female adults greater than or equal to 18 years old.

Previous enrollment on the P. vivax collection study.

Willingness to participate in the study as evidenced by written informed consent.

EXCLUSION CRITERIA: (Collection of peripheral blood for identifying and isolating memory B cells)

For the follow-up blood draw (250 mL), symptomatic parasitemia with any species of Plasmodium.

For the follow-up blood draw (250 mL), hemoglobin level < 9 g/dL.

For the follow-up blood draw (250 mL), weight < 45 kg.

Any condition that in the opinion of the investigator would render the subject unable to comply with the protocol (e.g., psychiatric illness).

Any health condition that in the opinion of the investigator would confound data analysis or pose unnecessary exposure risks to study personnel (e.g., individuals who are known to be HIV-infected or to have AIDS).

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00663546

Locations
Cambodia
National Center for Parasitology, Entomology, and Malaria Controk, Ministry of H
Phnom Penh, Cambodia
Preah Vihear Referral Hospital
Preah Vihear Province, Cambodia
Ratanakiri Referral Hospital
Ratanakiri Province, Cambodia
Sponsors and Collaborators
Investigators
Principal Investigator: Rick M Fairhurst, M.D. National Institute of Allergy and Infectious Diseases (NIAID)
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00663546     History of Changes
Other Study ID Numbers: 999908094, 08-I-N094
Study First Received: April 19, 2008
Last Updated: January 14, 2014
Health Authority: United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
Malaria
Plasmodium
Hemoglobin E
Alpha-thalssemia
G6PD deficiency

Additional relevant MeSH terms:
Malaria
Protozoan Infections
Parasitic Diseases

ClinicalTrials.gov processed this record on August 01, 2014